UAE Women’s Health Market Size & Outlook, 2023-2030
UAE women’s health market, 2018-2030 (US$M)
Related Markets
UAE women’s health market highlights
- The UAE women’s health market generated a revenue of USD 167.7 million in 2023 and is expected to reach USD 251.1 million by 2030.
- The UAE market is expected to grow at a CAGR of 5.9% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 167.7 million |
| Market revenue in 2030 | USD 251.1 million |
| Growth rate | 5.9% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, UAE accounted for 0.4% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia women’s health market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 323.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 36.67% in 2023. Horizon Databook has segmented the UAE women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing health concerns about lifestyle disorders, rising awareness about women's health, and growing prevalence of target diseases are some of the key factors driving the market in the country. According to International Osteoporosis Foundation, the estimated prevalence of osteoporosis hip fractures is 2.25 cases per 1,000 population annually in Abu Dhabi.
The UAE pharmaceuticals market is witnessing rapid growth. Although the UAE currently imports the majority of its pharmaceuticals, the scenario is expected to change, as some international pharmaceutical giants have partnered with UAE companies to manufacture products in the country.
Furthermore, the growing pharmaceutical sector in the UAE is another factor fueling the market growth. For instance, in February 2020, Neopharma and GSK plc launched the first locally produced batch of medicines. The main objective of this partnership is to generate manufacturing opportunities in the UAE.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE women’s health market size, by application, 2018-2030 (US$M)
UAE Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
